In 2016, meetings of groups of physicians and paediatricians with a special interest in lipid disorders and familial hypercholesterolaemia were held to discuss several domains of management of familial hypercholesterolaemia in adults and children in Hong Kong. After reviewing the evidence and guidelines for the diagnosis, screening, and management of familial hypercholesterolaemia, consensus was reached on the following aspects: clinical features, diagnostic criteria, screening in adults, screening in children, management in relation to target plasma low-density lipoprotein cholesterol levels, detection of atherosclerosis, lifestyle and behaviour modification, and pharmacotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.12809/hkmj187215 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ages at coronary heart disease and death in familial hypercholesterolaemia: a Danish nationwide study spanning 44 years.
Eur Heart J
January 2025
Department of Clinical Biochemistry, Copenhagen University Hospital-Herlev and Gentofte, Borgmester Ib Juuls Vej 73, DK-2730 Herlev, Denmark.
Background And Aims: Familial hypercholesterolaemia leads to lifelong elevated low-density lipoprotein cholesterol with increased risk of coronary heart disease and pre-mature death. It is unknown whether the prognosis for individuals with familial hypercholesterolaemia has improved over the past four decades as registration of this condition has been limited worldwide. However, in Danish nationwide registries, modified ICD coding has allowed such registration since 1978.
View Article and Find Full Text PDFFamilial hypercholesterolaemia: how to further improve outcomes.
Eur Heart J
January 2025
Division of Cardiovascular Disease, University of Alabama at Birmingham, 521 19th Street South-GSB 444, Birmingham, AL 35233, USA.
Cost-Effectiveness Analysis of Inclisiran for the Treatment of Primary Hypercholesterolemia or Mixed Dyslipidemia in Singapore.
Value Health Reg Issues
January 2025
Novartis Singapore Pte Ltd, Singapore. Electronic address:
Objectives: This analysis evaluated the cost-effectiveness of inclisiran plus standard of care (SoC; comprising statins, ezetimibe, and fenofibrate) in primary hypercholesterolemia or mixed dyslipidemia from a Singapore healthcare system perspective. Inclisiran + SoC was separately compared with SoC, alirocumab + SoC, and evolocumab + SoC.
Methods: A lifetime Markov model in the United Kingdom (UK) was adapted to the Singapore setting.
EHR-Based Screening of Familial Hypercholesterolemia: Finding the Lipid in the Haystack.
JACC Adv
December 2024
Department of Cardiovascular Medicine, Mayo Clinic, Scottsdale, Arizona, USA.
A Scoping Review of Electronic Health Records-Based Screening Algorithms for Familial Hypercholesterolemia.
JACC Adv
December 2024
Division of Blood Disorders and Public Health Genomics, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Background: Familial hypercholesterolemia (FH) is a common genetic disorder that is strongly associated with premature cardiovascular disease. Effective diagnosis and appropriate treatment of FH can reduce cardiovascular disease risk; however, FH is underdiagnosed. Electronic health record (EHR)-based FH screening tools have been previously described to enhance the detection of FH.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!